Trial Profile
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PEARL
- Sponsors AstraZeneca; AstraZeneca AB
- 28 Dec 2023 Planned End Date changed from 20 Aug 2026 to 4 Jun 2026.
- 16 Jun 2023 Planned End Date changed from 30 Jun 2026 to 20 Aug 2026.
- 31 Jan 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2026.